Edition:
India

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

17.46USD
23 Nov 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$17.46
Open
$17.52
Day's High
$18.22
Day's Low
$17.30
Volume
272,572
Avg. Vol
446,136
52-wk High
$24.70
52-wk Low
$1.76

Latest Key Developments (Source: Significant Developments)

Five Prime Therapeutics Q2 Loss Per Share $0.99
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS REPORTS SECOND QUARTER 2019 RESULTS.Q2 LOSS PER SHARE $0.99.Q2 EARNINGS PER SHARE ESTIMATE $-0.90 -- REFINITIV IBES DATA.FIVE PRIME THERAPEUTICS - CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES TOTALED $214.1 MILLION AS OF JUNE 30, 2019, VERSUS $237.0 MILLION AS OF MARCH 31, 2019.EXPECTS FULL-YEAR 2019 NET CASH USED IN OPERATING ACTIVITIES TO BE BETWEEN $117 AND $122 MILLION.ESTIMATES ENDING 2019 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BETWEEN $148 AND $153 MILLION..QTRLY COLLABORATION AND LICENSE REVENUE $3.3 MILLION VERSUS $7.6 MILLION.Q2 REVENUE VIEW $7.7 MILLION -- REFINITIV IBES DATA.  Full Article

Five Prime Therapeutics Reports Fourth Quarter Results
Wednesday, 27 Feb 2019 

Feb 26 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.12.Q4 EARNINGS PER SHARE ESTIMATE $-1.32 -- REFINITIV IBES DATA.COLLABORATION AND LICENSE REVENUE FOR Q4 OF 2018 DECREASED BY $9.2 MILLION TO $4.0 MILLION FROM $13.2 MILLION FOR Q4 OF 2017.EXPECTS FULL-YEAR 2019 NET CASH USED IN OPERATING ACTIVITIES TO BE BETWEEN $117 AND $122 MILLION.ESTIMATES ENDING 2019 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BETWEEN $148 AND $153 MILLION.MULTIPLE DATA READOUTS IN 2019.  Full Article

Five Prime Therapeutics Estimates Its Cash, Cash Equivalents And Marketable Securities As Of Dec 31, 2018 Was About $270.1 Mln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS - ESTIMATES ITS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2018 WAS ABOUT $270.1 MILLION.FIVE PRIME THERAPEUTICS - EXPECTS NET CASH USED IN OPERATING ACTIVITIES FOR FISCAL YEAR 2019 WILL BE BETWEEN $117 MILLION AND $122 MILLION.FIVE PRIME THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES AS OF DEC 31, 2019 WILL BE BETWEEN $148 MILLION AND $153 MILLION - SEC FILING.  Full Article